2014•European Journal of CancerRequires access

457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamide

Barry R. Davies, Andrew Thomason, Rebecca Ellston, Hayley Campbell, Celina M. D’Cruz, Alessia Mazzola, Tingting Zhou, Joseph S. Schmidt, Min-Jeong Jo, Yoon-Keun Kim, A. Robert McLeod, D C Blakey, Nigel Brooks

Open publisher page 4 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Enzalutamide, Androgen receptor, LNCaP, Prostate cancer, Cancer research, Dihydrotestosterone, Androgen, Biology